New Japanese Drug Pemafibrate Improves Lipid Profiles in Diabetes - Medscape


Medscape

New Japanese Drug Pemafibrate Improves Lipid Profiles in Diabetes
Medscape
Pemafibrate (Kowa Company), a novel selective peroxisome proliferator-activated receptor alpha (PPARα) modulator (or fibrate), may significantly improve lipid profiles and insulin resistance in patients with type 2 diabetes and hypertriglyceridemia ...



from diabetes - Google News